Citation Impact
Citing Papers
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
2016
Factors Associated With Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis
2008 Standout
Oral cavity and oropharyngeal squamous cell carcinoma—an update
2015 Standout
Pathogenesis and treatment of psoriasis: exploiting pathophysiological pathways for precision medicine.
2015
Head and neck squamous cell carcinoma
2020 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Dendritic cells in cancer immunology and immunotherapy
2019 Standout
Psoriasis
2014
Positron emission tomography–computed tomography surveillance for the node‐positive neck after chemoradiotherapy
2009
The role of JAK/STAT signaling pathway and its inhibitors in diseases
2020
Rheumatoid arthritis
2016 Standout
Radiation Doses to Structures Within and Adjacent to the Larynx are Correlated With Long-Term Diet- and Speech-Related Quality of Life
2007
JAKs and STATs in Immunity, Immunodeficiency, and Cancer
2013
Heterogeneity in head and neck IMRT target design and clinical practice
2012
A systematic review and meta‐analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy
2008
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
2017
Clinical Significance of Postradiotherapy [18F]-Fluorodeoxyglucose Positron Emission Tomography Imaging in Management of Head-and-Neck Cancer—A Long-Term Outcome Report
2008
Tumor Cell Metabolism: Cancer's Achilles' Heel
2008 Standout
Psoriasis
2021 Standout
Treatment of oral squamous cell carcinoma using anti-HER2 immunonanoshells
2011
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis
2011
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
2012
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
2014
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Results of a prospective study of positron emission tomography–directed management of residual nodal abnormalities in node‐positive head and neck cancer after definitive radiotherapy with or without systemic therapy
2011
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Crohn's disease
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
2020
Ulcerative colitis
2016 Standout
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
2019
10 Years of GWAS Discovery: Biology, Function, and Translation
2017 Standout
Ulcerative colitis
2020 Standout
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers
2006
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
2017
Delineation of the neck node levels for head and neck tumors: A 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines
2013 Standout
Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial
2015
Calprotectin (S100A8/S100A9): a key protein between inflammation and cancer
2018
Biological Therapies for Atopic Dermatitis: A Systematic Review
2021
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
2013
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
2017
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
2017 Standout
Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
2015
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
2017
Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
2014
Head and Neck Cancer
2020 Standout
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
2016
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
2015
Psoriasis Pathogenesis and Treatment
2019 Standout
Interventions for preventing oral mucositis for patients with cancer receiving treatment
2011
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
2018
Artificial intelligence in cancer imaging: Clinical challenges and applications
2019 Standout
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Interventions for treating oral mucositis for patients with cancer receiving treatment
2010
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases
2020
Concurrent Chemoradiotherapy for Locally Advanced, Nonmetastatic, Squamous Carcinoma of the Head and Neck: Consensus, Controversy, and Conundrum
2006
Inflammatory responses and inflammation-associated diseases in organs
2017 Standout
Measurement of Organ-Specific and Acute-Phase Blood Protein Levels in Early Lyme Disease
2019 StandoutNobel
Transoral laser microsurgery for treatment for hypopharyngeal cancer in 211 patients
2017
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of Huaming Tan being referenced
CD147/EMMPRIN overexpression and prognosis in cancer: A systematic review and meta-analysis
2016
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
2015
Changing Failure Patterns in Oropharyngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiotherapy and Implications for Future Research
2006
Effects of tofacitinib on cardiovascular risk factors and cardiovascular outcomes based on phase III and long-term extension data in patients with plaque psoriasis
2016
Pathology and FDG PET Correlation of Residual Lymph Nodes in Head and Neck Cancer After Radiation Treatment
2007
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study
2016
The Failure Patterns of Oral Cavity Squamous Cell Carcinoma After Intensity-Modulated Radiotherapy—The University of Iowa Experience
2007
Is Planned Neck Dissection Necessary for Head and Neck Cancer After Intensity-Modulated Radiotherapy?
2007
Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma—the University of Iowa experience
2005
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment
2005
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
2012
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study
2016
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
2014
Tofacitinib (CP ‐690,550), an oral Janus kinase inhibitor, improves patient‐reported outcomes in a phase 2b, randomized, double‐blind, placebo‐controlled study in patients with moderate‐to‐severe psoriasis
2013
Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.
2014
[The second phase clinical observation of anti-radiation effect by superoxide dismutase].
1998
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
2013
Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study
2018